Skip to Content

Join the 'Cytomegalovirus (CMV) Infection' group to help and get support from people like you.

Cytomegalovirus (CMV) Infection News

Related terms: CMV, congenital, CMV Infection, Congenital cytomegalovirus (CMV), Congenital cytomegalovirus

Virus Present at Birth Causes More Than 10 Percent of Hearing-Loss Cases in Kids

Posted 27 Oct 2014 by Drugs.com

MONDAY, Oct. 27, 2014 – More than 10 percent of babies born with an infection called cytomegalovirus will suffer permanent hearing loss, a new study reports. But only one in 10 children with the virus shows symptoms, and screening is not routine, said study lead researcher Dr. Julie Goderis, of University Hospital Ghent in Belgium. Cytomegalovirus (CMV) is the most common non-inherited cause of hearing loss in children, responsible in 10 percent to 20 percent of cases, the researchers noted. "Until a vaccine becomes available, behavioral and educational interventions are the most effective strategy to prevent mothers from being infected with CMV," she said. Previous research has shown that mothers usually get the virus from toddlers. Once infected, she can pass the infection to the fetus, the researchers said. "Following-up a child's hearing until the age of 6 years is essential to ... Read more

Related support groups: Hearing Loss, Cytomegalovirus (CMV) Infection

Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds

Posted 23 Sep 2014 by Drugs.com

TUESDAY, Sept. 23, 2014 – For babies born at very low birth weights, breast milk is more likely than a blood transfusion to lead to a potentially dangerous infection known as cytomegalovirus (CMV), a new study finds. The researchers evaluated more than 500 very low birth weight infants – all of whom weighed 3.3 pounds or less and many who were born to mothers with a history of CMV infection, to see whether breast milk or transfusions carried the bigger risk. Infants born at very low birth weights are especially vulnerable to this viral infection, the study authors noted. Of 29 babies who developed CMV, none were linked to blood transfusions. But, 27 were linked to breast milk, the study found. "We didn't know we were going to find so much CMV in breast milk," said study corresponding author Dr. Cassandra Josephson, a professor of pathology and pediatrics at Emory University School of ... Read more

Related support groups: Cytomegalovirus (CMV) Infection, Prematurity/Underweight in Infancy

Test Approved to Help Treat Common Infection in Transplant Patients

Posted 5 Jul 2012 by Drugs.com

THURSDAY, July 5 – The first DNA test to help doctors treat a common viral infection in people who have had a solid organ transplant has been approved by the U.S. Food and Drug Administration. The cytomegalovirus (CMV) is a common viral infection, especially in people who have had their immune systems deliberately suppressed after an organ transplant. Among those who have had transplants of organs such as the heart, lung, pancreas or kidney, the virus can lead to diseases such as pneumonia or colitis, the FDA said in a news release. Doctors commonly suppress the immune system to help prevent rejection of the transplanted organ, and may have to prescribe an anti-CMV therapy. Depending on a patient's increase or decrease in viral load as determined by the new test, doctors can measure a therapy's effectiveness. The COBAS AmpliPrep/COBAS TaqMan CMV Test was evaluated in clinical studies ... Read more

Related support groups: Cytomegalovirus (CMV) Infection

Saliva Test Spots Virus That Can Cause Hearing Loss in Newborns

Posted 2 Jun 2011 by Drugs.com

THURSDAY, June 2 – A new study finds that a saliva test in newborns can detect almost all cases of a virus that can cause birth defects and hearing loss. The test could allow doctors to get a head start on preventing or treating deafness in children infected with the virus, known as cytomegalovirus. The traditional "heel stick" blood test for newborns doesn't do a good job of detecting the infection, which is passed from mother to child and affects tens of thousands of babies each year, although most don't suffer any ill effects. The test misses 60 percent to 70 percent of cases. Cytomegalovirus is "the epidemic that nobody's ever heard of," said Dr. Mark Schleiss, director of the University of Minnesota Medical School's division of pediatric infectious diseases and immunology. "This virus causes more birth defects in babies than any other infectious disease in the United States ... Read more

Related support groups: Hearing Loss, Cytomegalovirus (CMV) Infection

Demystifying a Common, Persistent Virus

Posted 2 Apr 2010 by Drugs.com

THURSDAY, April 1 – New research sheds light on how a virus known as cytomegalovirus (CMV), which infects up to 80 percent of the U.S. population before age 40, re-infects people again and again even though their immune systems strongly respond to it. The infection doesn't always make people ill, but certain people, such as newborns and others with weakened immune systems, can develop serious symptoms and disabilities. "CMV is one of a few virus types that can efficiently re-infect individuals who are already persistently infected by this virus," Dr. Louis Picker, an associate director of Oregon Health & Science University's Vaccine and Gene Therapy Institute, said in a news release. "When most viruses infect a host, the immune system remembers the disease and protects against re-infection. This is the case with smallpox, seasonal strains of flu and several other viruses," Picker said. ... Read more

Related support groups: Cytomegalovirus (CMV) Infection

Extended Antiviral May Benefit Kidney Transplant Patients

Posted 2 Feb 2010 by Drugs.com

THURSDAY, Sept. 17 – A longer period of preventive treatment after kidney transplant can help reduce the risk that the patient will become infected with a virus that can cause devastating problems, new research suggests. Healthy people can usually fight off the virus, called cytomegalovirus, but those with kidney transplants have weakened immune systems and are more susceptible to infection, the authors of the study noted in a news release from the American Society of Nephrology. In the comparison study, Dr. Fu Luan, of the University of Michigan in Ann Arbor, and colleagues gave kidney transplant patients either three months or six months of treatment with the antiviral drug valganciclovir. They found that those who were given the longer treatment had a rate of infection that was half that of those who received treatment for three months (12 percent vs. 24 percent). When the ... Read more

Related support groups: Cytomegalovirus (CMV) Infection, Valcyte, Valganciclovir

FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants

Posted 2 Dec 2009 by Drugs.com

- Plus new oral solution offers dosing flexibility for pediatric patients - NUTLEY, N.J., Aug. 31 /PRNewswire-FirstCall/ – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease. The FDA also approved a new pediatric oral solution formulation for Valcyte, which will allow easier administration to pediatric patients 4 months to 16 years of age. "Children receiving organ transplants are especially vulnerable to infection because of their reduced immunity, and the invasive procedure of a transplant can put them at higher risk of contracting CMV infection," noted Richard Freeman, M.D., Vice Chair for Research, Department of ... Read more

Related support groups: Cytomegalovirus (CMV) Infection, Valcyte

Viral Infection Might Trigger High Blood Pressure

Posted 15 May 2009 by Drugs.com

FRIDAY, May 15 – A hidden viral infection that most adults harbor could be a cause of high blood pressure, animal studies indicate. Mice infected with cytomegalovirus (CMV) were more likely to develop not only high blood pressure but also the hardening of the arteries called atherosclerosis, according to a report in the May 15 issue of PLoS Pathogens by researchers at Beth Israel Deaconess Hospital in Boston. "This could be of immense importance," said lead researcher Dr. Clyde Crumpacker, a professor of medicine at Harvard Medical School and an investigator in the Division of Infectious Diseases at Beth Israel Deaconess. "The implication for the human population is that antiviral therapy or a vaccine could be an intervention for high blood pressure." CMV infection is widespread, Crumpacker noted. Studies indicate that between 60 percent and 99 percent of adults worldwide are infected, ... Read more

Related support groups: Cytomegalovirus (CMV) Infection

Trial Vaccine May Protect Against Serious Viral Infection

Posted 18 Mar 2009 by Drugs.com

WEDNESDAY, March 18 – Women who were given an experimental vaccine for a viral infection that can cause serious problems in babies, known as cytomegalovirus, reduced their risk of infection by 50 percent for as long as three and half years after vaccination, according to new research. "In many ways, this was a surprising result," said the lead author of the study, Dr. Robert Pass, a professor of pediatrics at the University of Alabama at Birmingham. "Many people in the field felt it would be very difficult to prevent infection in mothers. We thought the best we could hope for was a vaccine for women that would prevent infection in a baby." Results of the study are published in the March 19 issue of the New England Journal of Medicine. Cytomegalovirus, or CMV, causes severe hearing, mental or movement impairments each year in about 8,000 infants who develop the infection while still in ... Read more

Related support groups: Cytomegalovirus (CMV) Infection

Ask a Question

Further Information

Related Condition Support Groups

CMV Retinitis, CMV Pneumonia, CMV Gastroenteritis, Viral Infection

Related Drug Support Groups

Valtrex, valacyclovir, Valcyte, ganciclovir, valganciclovir, cytomegalovirus immune globulin, CytoGam, Cytovene